Autopsy report · NCT01032122
Rituximab in Metastatic Melanoma
Cause of deathSlow enrollment
“the only reason is that recruitment was not sufficient to meet the planned patient numbers, because complete remissions are still infrequent.”
Life of this trial
- Registered 1 year 11 months after it had already started.
- Ran for about 3 years 7 months before it stopped.
- 9 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Melanoma
- Interventions
- rituximab
- Participants
- 9
- Sites
- 1
- Countries
- Austria
Trials that died the same way
- Prospective Study of the sensiTVT
“The recruitment proceeded much slower than expected. The planned number of patients could not be reached within the planned time.” - Changes in Abdominal Tissues Induced by Magnetic Device - CT Evaluation
“It wasn't possible to recruit the desired number of patients.” - Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus
“Patient recruitment was not sufficient to achieve the needed patient numbers.” - Sevoflurane and Laryngeal Reflex Responses in Pediatric Patients
“Recruitment finished earlier, because all 40 patients enrolled” - Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
“No more patients complying the selection criteria were available for recruitment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.